|
LUNG CANCER, SUSCEPTIBILITY TO
|
|
0.700 |
SusceptibilityMutation
|
CLINVAR |
|
|
|
|
Leukemia, Myelocytic, Acute
|
|
0.020 |
GeneticVariation
|
BEFREE |
Fas−1377G>A (rs2234767), −670T>C (rs1800682), and FasL−844T>C (rs763110) polymorphisms in 592 AML patients and 858 healthy controls were genotyped and tested for associations between polymorphisms and AML risk.
|
20438363 |
2010 |
|
Squamous cell carcinoma of esophagus
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haplotype analysis indicated that the FAS polymorphisms -670 A > G (rs1800682) and -1377 G > A (rs2234767) were both associated with OSCC in the Mixed Ancestry population (P = 0.006 and P = 0.004, respectively), as well as the CASP8 (-652 6Ndel:302His) haplotype (P = 0.0013).
|
21926110 |
2011 |
|
Leukemia, Myelocytic, Acute
|
|
0.020 |
GeneticVariation
|
BEFREE |
We investigated a common G > A polymorphism at position -1377 (rs2234767) in the core promoter of the CD95 cell death receptor gene in 708 subjects with acute myeloid leukemia, including 231 patients with APL.
|
22084312 |
2012 |
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
We investigated a common G > A polymorphism at position -1377 (rs2234767) in the core promoter of the CD95 cell death receptor gene in 708 subjects with acute myeloid leukemia, including 231 patients with APL.
|
22084312 |
2012 |
|
Lupus Erythematosus, Systemic
|
|
0.010 |
GeneticVariation
|
BEFREE |
The Fas gene polymorphisms -670A/G (rs1800682) and -1377G/A (rs2234767) have been shown to be associated with systemic lupus erythematosus (SLE), but findings are not consistent.
|
23065220 |
2013 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, FAS rs2234767 was not associated with breast cancer risk.
|
23326385 |
2013 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, FAS rs2234767 was not associated with breast cancer risk.
|
23326385 |
2013 |
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls.
|
24014103 |
2013 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls.
|
24014103 |
2013 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Studies on the association between the FAS/FASL polymorphisms (FAS-1377G/A rs2234767, FAS-670A/G rs1800682, and FASL-844C/T rs763110) and breast cancer risk have reported inconsistent results.
|
24248546 |
2014 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Studies on the association between the FAS/FASL polymorphisms (FAS-1377G/A rs2234767, FAS-670A/G rs1800682, and FASL-844C/T rs763110) and breast cancer risk have reported inconsistent results.
|
24248546 |
2014 |
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
Further studies on a larger sample size and considering gene-environment interactions should be conducted to confirm the role of FAS polymorphisms, especially rs2234767G/A, in cancer risk.
|
24568648 |
2014 |
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
We found that the rs2234767 G-allele was a protective factor for cancer risk (GG vs. AA: OR=0.88, 95% CI=0.79-0.98; GG+GA vs. AA: OR=0.87, 95% CI=0.79-0.96).
|
24568648 |
2014 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Further studies on a larger sample size and considering gene-environment interactions should be conducted to confirm the role of FAS polymorphisms, especially rs2234767G/A, in cancer risk.
|
24568648 |
2014 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
We found that the rs2234767 G-allele was a protective factor for cancer risk (GG vs. AA: OR=0.88, 95% CI=0.79-0.98; GG+GA vs. AA: OR=0.87, 95% CI=0.79-0.96).
|
24568648 |
2014 |
|
Stage IIA Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hence, the present study aimed to investigate the association of functional SNPs of DR4 (rs20575, rs20576 and rs6557634), FAS (rs2234767) and FASL (rs763110) with gallbladder cancer (GBC) risk.
|
24587306 |
2014 |
|
Stage 0 Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hence, the present study aimed to investigate the association of functional SNPs of DR4 (rs20575, rs20576 and rs6557634), FAS (rs2234767) and FASL (rs763110) with gallbladder cancer (GBC) risk.
|
24587306 |
2014 |
|
Stage IV Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hence, the present study aimed to investigate the association of functional SNPs of DR4 (rs20575, rs20576 and rs6557634), FAS (rs2234767) and FASL (rs763110) with gallbladder cancer (GBC) risk.
|
24587306 |
2014 |
|
Stage III Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hence, the present study aimed to investigate the association of functional SNPs of DR4 (rs20575, rs20576 and rs6557634), FAS (rs2234767) and FASL (rs763110) with gallbladder cancer (GBC) risk.
|
24587306 |
2014 |
|
Gallbladder Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hence, the present study aimed to investigate the association of functional SNPs of DR4 (rs20575, rs20576 and rs6557634), FAS (rs2234767) and FASL (rs763110) with gallbladder cancer (GBC) risk.
|
24587306 |
2014 |
|
Malignant neoplasm of gallbladder
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hence, the present study aimed to investigate the association of functional SNPs of DR4 (rs20575, rs20576 and rs6557634), FAS (rs2234767) and FASL (rs763110) with gallbladder cancer (GBC) risk.
|
24587306 |
2014 |
|
Stage IIB Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hence, the present study aimed to investigate the association of functional SNPs of DR4 (rs20575, rs20576 and rs6557634), FAS (rs2234767) and FASL (rs763110) with gallbladder cancer (GBC) risk.
|
24587306 |
2014 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin.
|
26759270 |
2016 |
|
Multiple tumors
|
|
0.010 |
GeneticVariation
|
BEFREE |
FAS rs2234767 (-1377 G>A), rs1800682 (-670 A>G) and FASLG rs763110 (-844 C>T) promoter polymorphisms can influence transcriptional activities of the genes and thus multiple tumors susceptibility.
|
26759270 |
2016 |